Technical Analysis for PTN - Palatin Technologies, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Historical PTN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Spinning Top | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | -4.63% | |
| Calm After Storm | Range Contraction | -4.63% | |
| Wide Bands | Range Expansion | -4.63% | |
| Oversold Stochastic | Weakness | -4.63% | |
| Crossed Above 50 DMA | Bullish | -8.31% | |
| Calm After Storm | Range Contraction | -8.31% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakdown | 1 day ago | |
| Down 5% | 1 day ago | |
| Fell Below Previous Day's Low | 1 day ago | |
| Down 3% | 1 day ago | |
| Down 2 % | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/17/2021
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Diseases Molecular Biology Drug Development Dysfunction Endocrine System Obesity Peptides C Peptide Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Diseases Molecular Biology Drug Development Dysfunction Endocrine System Obesity Peptides C Peptide Male Sexual Dysfunction Melanocortin Sexual Dysfunction Treatment Of Obesity
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.3 |
| 52 Week Low | 0.35 |
| Average Volume | 8,694,365 |
| 200-Day Moving Average | 0.58 |
| 50-Day Moving Average | 0.83 |
| 20-Day Moving Average | 0.97 |
| 10-Day Moving Average | 0.91 |
| Average True Range | 0.11 |
| ADX | 28.54 |
| +DI | 20.32 |
| -DI | 29.19 |
| Chandelier Exit (Long, 3 ATRs ) | 0.97 |
| Chandelier Exit (Short, 3 ATRs ) | 1.06 |
| Upper Bollinger Band | 1.23 |
| Lower Bollinger Band | 0.70 |
| Percent B (%b) | 0.15 |
| BandWidth | 55.04 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.0429 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.86 | ||||
| Resistance 3 (R3) | 0.87 | 0.84 | 0.85 | ||
| Resistance 2 (R2) | 0.84 | 0.82 | 0.84 | 0.85 | |
| Resistance 1 (R1) | 0.81 | 0.81 | 0.80 | 0.81 | 0.84 |
| Pivot Point | 0.79 | 0.79 | 0.78 | 0.79 | 0.79 |
| Support 1 (S1) | 0.76 | 0.77 | 0.75 | 0.75 | 0.72 |
| Support 2 (S2) | 0.73 | 0.75 | 0.73 | 0.72 | |
| Support 3 (S3) | 0.70 | 0.73 | 0.71 | ||
| Support 4 (S4) | 0.70 |
